Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032

Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032

The global bleeding disorders market size is expected to reach USD 27.49 billion by 2032, according to a new study by Polaris Market Research. The report “Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The most prevalent kind of hemophilia is hemophilia A. It occurs when there is insufficient clotting factor 8. According to the Centres for Disease Control and Prevention (CDC), hemophilia A affects roughly 10 in every 100,000 persons in the United States. When clotting factor 9 levels are insufficient, hemophilia B develops. According to the CDC, hemophilia B affects roughly 3 in 100,000 Americans. This is driving the growth and demand for the bleeding disorders market in coming years.

The increasing prevalence of hemophilia A, greater awareness and screening for the disease, advances in new therapies, and the longer life expectancy of patients with the disease are all contributing factors to the growth of the bleeding disorders market. According to Statista, Hemophilia A affected 185,318 persons globally in 2021, while another 17,951 people had various platelet diseases. As more patients are diagnosed with hemophilia A and B, the demand for clotting factor replacement therapy increases, which fuels the growth of the market.

Bleeding disorders, such as hemophilia and von Willebrand disease, are characterized by a deficiency or dysfunction of clotting factors in the blood. Patients with bleeding disorders require regular infusions of clotting factor replacement therapy to prevent or control bleeding episodes. These clotting factors are primarily derived from donated blood and plasma. In order to produce these clotting factors, donor blood and plasma must be available.

Due to the rising prevalence of bleeding diseases, there is an increase in need for blood donations as well as clotting factor replacement therapy. According to the World Health Organization, 119 nations have recorded an increase in voluntary unpaid blood donations of 10.7 million from 2008 to 2018. This will create a wide range of opportunities for the growth of the bleeding disorders market.

HBV causes 600,000 to 1.2 million fatalities annually, with 15-40% of infected patients developing fatal liver conditions (cirrhosis, liver failure, and hepatocellular carcinoma). Patients with liver cirrhosis and HCC are at an increased risk of developing bleeding disorders due to the decreased production of clotting factors by the liver. As a result, the demand for clotting factor replacement therapy is high among these patients, which fuels the growth of the market.

Bleeding Disorders Market Report Highlights

Hemophilia A Type is anticipated to grow due to the increasing prevalence of hemophilia A and rising demand for novel therapies.

Recombinant Coagulation Factor Concentrates segment accounted for the higher growth rate owing to the growing demand for prophylaxis and advancements in manufacturing technology.

Asia Pacific is expected to grow at a significant growth rate owing to the increasing prevalence of bleeding disorders and investments in research & development.

The global players include Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol, Sanofi, Amgen, Janssen, and Bioverativ Inc.

Polaris Market Research has segmented the bleeding disorders market report based on type, drug class and region:

Bleeding Disorders, Type Outlook (Revenue - USD Billion, 2019 - 2032)

Hemophilia A

Hemophilia B

Von Willebrand Diseases

Bleeding Disorders, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Plasma Derived Coagulation Factor Concentrates

Recombinant Derived Coagulation Factor

Desmopressin

Antifibrinolytics

Fibrin Sealants

Bleeding Disorders, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa